Cargando…

Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy

ABSTRACT: INTRODUCTION/AIMS: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patient’s ability to walk and perform activities of daily living independently. Furthermore, patients often report fatigue and depr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klehmet, Juliane, Tackenberg, Björn, Haas, Judith, Kieseier, Bernd C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214666/ https://www.ncbi.nlm.nih.gov/pubmed/37237267 http://dx.doi.org/10.1186/s12883-023-03223-5

Ejemplares similares

Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy
por: Talaei, M., et al.
Publicado: (2021)

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
por: Cornblath, David R., et al.
Publicado: (2023)

Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
por: Mahdi-Rogers, Mohamed, et al.
Publicado: (2010)

Calprotectin in Chronic Inflammatory Demyelinating Polyneuropathy and Variants—A Potential Novel Biomarker of Disease Activity
por: Stascheit, Frauke, et al.
Publicado: (2021)

Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy
por: Klehmet, Juliane, et al.
Publicado: (2019)

Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy
por: Khoo, Anthony, et al.
Publicado: (2019)

Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes
por: Diederich, Jan-Markus, et al.
Publicado: (2018)

Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy
por: Stettner, Mark, et al.
Publicado: (2015)

Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy
por: Goyal, Namita A., et al.
Publicado: (2021)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US
por: Guptill, Jeffrey T, et al.
Publicado: (2019)

A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy
por: Gable, Karissa L., et al.
Publicado: (2022)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
por: Markvardsen, Lars K., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective
por: Cocito, Dario, et al.
Publicado: (2023)

Chronic inflammatory demyelinating polyneuropathy (CIDP): change of serum IgG dimer levels during treatment with intravenous immunoglobulins
por: Ritter, Christian, et al.
Publicado: (2015)

Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy
por: Seino, Yusuke, et al.
Publicado: (2018)

Depression with Chronic Inflammatory Demyelinating Polyneuropathy
por: Marwale, Arun, et al.
Publicado: (2018)

Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study
por: Adrichem, M. E., et al.
Publicado: (2019)

Subcutaneous Immunoglobulin in Infantile Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report
por: Cianci, Paola, et al.
Publicado: (2019)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins
por: Finsterer, Josef, et al.
Publicado: (2017)

Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022)

High-dose immunoglobulin-dependent chronic demyelinating inflammatory polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis
por: Hiya, Satomi, et al.
Publicado: (2022)

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
por: Tortorici, Michael A., et al.
Publicado: (2021)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy
por: Castle, Dan, et al.
Publicado: (2019)

Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A., et al.
Publicado: (2018)

Neurofascin (NF)155- and NF186-Specific T Cell Response in a Patient Developing a Central Pontocerebellar Demyelination after 10 Years of CIDP
por: Klehmet, Juliane, et al.
Publicado: (2017)

Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy
por: Kuitwaard, Krista, et al.
Publicado: (2021)

A Case of Paraneoplastic Demyelinating Motor Polyneuropathy
por: Mostoufizadeh, Sohrab, et al.
Publicado: (2012)

Tailoring of therapy for chronic inflammatory demyelinating polyneuropathy
por: Rajabally, Yusuf A.
Publicado: (2015)

Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy
por: Allen, Jeffrey A., et al.
Publicado: (2018)

The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy
por: Bril, Vera, et al.
Publicado: (2016)

Anesthetic management of a patient with chronic inflammatory demyelinating polyneuropathy by combination of total intravenous and regional anesthesia
por: Takekawa, Daiki, et al.
Publicado: (2019)

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis
por: Perraudin, Clémence, et al.
Publicado: (2020)

Predicting the Response to Intravenous Immunoglobulins in an Animal Model of Chronic Neuritis
por: Meyer zu Horste, Gerd, et al.
Publicado: (2016)

IRIS manifesting as chronic inflammatory demyelinating polyneuropathy in HIV
por: Reghukumar, Aravind, et al.
Publicado: (2014)

Chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus
por: Fatehi, Farzad, et al.
Publicado: (2013)

Chronic Acquired Demyelinating Polyneuropathy following Renal Transplantation
por: Younger, D. S., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t2bqrq7jdqn7g56lvsp8aqvqav